ArticleNature communications2026
A non-invasive end-to-end intelligent assistance system for breast ultrasound.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
49 authors.
Funding
Abstract
Although artificial intelligence enhances medical image classification to effectively improve lesion diagnosis accuracy and efficiency, it still faces generalization challenges in breast ultrasound and its clinical potential remains underutilized in complex real-world scenarios. Here, we develop and test an end-to-end breast intelligent recognition device (BIRD) for women across diverse institution/population datasets. The accuracy of BIRD in the internal test set is 0.837 (95% confidence interval: 0.827-0.846), which significantly improves radiologists' accuracy in 2 reader studies (P < 0.05). BIRD is applied in breast cancer screening for 6,817 individuals and shows high consistency (Cohen's kappa: 0.702 (95% confidence interval: 0.628-0.777)) with clinical assessments in real-world application across 107 hospitals. Pathological and molecular subtype models developed using data from five hospitals also exhibit satisfactory classification performance. These findings confirm BIRD's ability to improve diagnostic accuracy, assist screening, and characterize breast lesions, facilitating clinical adoption in breast health practice. The Chinese Clinical Trial Register: ChiCTR2300073777.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.